Gonadal recovery following hematopoietic stem cell transplantation in male patients
| Type of HSCT . | Regimen . | Disease . | Number . | Age at HSCT median (range), years . | Years post-transplant, median (range), years . | Gonadal recovery . | Outcome of pregnancies . | Reference . |
|---|---|---|---|---|---|---|---|---|
| Allogeneic | CY | AA | 109 | 24 (13–52) | 3 (1–19) | 61% | 51 live births, 4 spontaneous abortions and 7 elective abortions in 62 pregnancies of 28 patient’s partners | (21) |
| Allogeneic | CY | AA | 10 | Mean 23 | Mean 2.5 (1–15) | 90% | 4 live births in 4 patient’s partners | (22) |
| Allogeneic | CY/TBI (10 Gy) | HM | 59 | 23 (12–59) | 5 (1–19) | 20% | 8 live births in 8 pregnancies of 5 patient’s partners | (21) |
| CY/TBI (12 Gy) | HM | 226 | 31 (11–62) | 4 (1–14) | 16% | |||
| CY/TBI (>12 Gy) | HM | 166 | 26 (13–54) | 4 (1–13) | 18% | |||
| Allogeneic | CY/TBI (9.5–14.4 Gy) | HM | 11 | 33 (19–47) | 3 (1–9) | 9% | NA | (23) |
| Allogeneic | CY/TBI or CY/TAI | HM | 48 | mean 27 | mean5.6 (1–18) | 15% | 1 live birth in 1 patient’s partner | (22) |
| Allogeneic | BU/CY | HM | 46 | 34 (13–56) | 2 (1–5) | 17% | 4 live births in 4 pregnancies of 2 patient’s partners | (21) |
| Autologous | BEAM | HL, NHL | 10 | 30.5 (17–53) | 2.5 (0.1–5) | 0 | No recovery | (23) |
| Type of HSCT . | Regimen . | Disease . | Number . | Age at HSCT median (range), years . | Years post-transplant, median (range), years . | Gonadal recovery . | Outcome of pregnancies . | Reference . |
|---|---|---|---|---|---|---|---|---|
| Allogeneic | CY | AA | 109 | 24 (13–52) | 3 (1–19) | 61% | 51 live births, 4 spontaneous abortions and 7 elective abortions in 62 pregnancies of 28 patient’s partners | (21) |
| Allogeneic | CY | AA | 10 | Mean 23 | Mean 2.5 (1–15) | 90% | 4 live births in 4 patient’s partners | (22) |
| Allogeneic | CY/TBI (10 Gy) | HM | 59 | 23 (12–59) | 5 (1–19) | 20% | 8 live births in 8 pregnancies of 5 patient’s partners | (21) |
| CY/TBI (12 Gy) | HM | 226 | 31 (11–62) | 4 (1–14) | 16% | |||
| CY/TBI (>12 Gy) | HM | 166 | 26 (13–54) | 4 (1–13) | 18% | |||
| Allogeneic | CY/TBI (9.5–14.4 Gy) | HM | 11 | 33 (19–47) | 3 (1–9) | 9% | NA | (23) |
| Allogeneic | CY/TBI or CY/TAI | HM | 48 | mean 27 | mean5.6 (1–18) | 15% | 1 live birth in 1 patient’s partner | (22) |
| Allogeneic | BU/CY | HM | 46 | 34 (13–56) | 2 (1–5) | 17% | 4 live births in 4 pregnancies of 2 patient’s partners | (21) |
| Autologous | BEAM | HL, NHL | 10 | 30.5 (17–53) | 2.5 (0.1–5) | 0 | No recovery | (23) |
CY, cyclophosphamide; AA, aplastic anemia; HM, hematological malignancy; NA, not assessed; TAI, thoracoabdominal irradiation; BU, busulfan; BEAM, carmustine, etoposide, cytarabine and melphalan.
Gonadal recovery following hematopoietic stem cell transplantation in male patients
| Type of HSCT . | Regimen . | Disease . | Number . | Age at HSCT median (range), years . | Years post-transplant, median (range), years . | Gonadal recovery . | Outcome of pregnancies . | Reference . |
|---|---|---|---|---|---|---|---|---|
| Allogeneic | CY | AA | 109 | 24 (13–52) | 3 (1–19) | 61% | 51 live births, 4 spontaneous abortions and 7 elective abortions in 62 pregnancies of 28 patient’s partners | (21) |
| Allogeneic | CY | AA | 10 | Mean 23 | Mean 2.5 (1–15) | 90% | 4 live births in 4 patient’s partners | (22) |
| Allogeneic | CY/TBI (10 Gy) | HM | 59 | 23 (12–59) | 5 (1–19) | 20% | 8 live births in 8 pregnancies of 5 patient’s partners | (21) |
| CY/TBI (12 Gy) | HM | 226 | 31 (11–62) | 4 (1–14) | 16% | |||
| CY/TBI (>12 Gy) | HM | 166 | 26 (13–54) | 4 (1–13) | 18% | |||
| Allogeneic | CY/TBI (9.5–14.4 Gy) | HM | 11 | 33 (19–47) | 3 (1–9) | 9% | NA | (23) |
| Allogeneic | CY/TBI or CY/TAI | HM | 48 | mean 27 | mean5.6 (1–18) | 15% | 1 live birth in 1 patient’s partner | (22) |
| Allogeneic | BU/CY | HM | 46 | 34 (13–56) | 2 (1–5) | 17% | 4 live births in 4 pregnancies of 2 patient’s partners | (21) |
| Autologous | BEAM | HL, NHL | 10 | 30.5 (17–53) | 2.5 (0.1–5) | 0 | No recovery | (23) |
| Type of HSCT . | Regimen . | Disease . | Number . | Age at HSCT median (range), years . | Years post-transplant, median (range), years . | Gonadal recovery . | Outcome of pregnancies . | Reference . |
|---|---|---|---|---|---|---|---|---|
| Allogeneic | CY | AA | 109 | 24 (13–52) | 3 (1–19) | 61% | 51 live births, 4 spontaneous abortions and 7 elective abortions in 62 pregnancies of 28 patient’s partners | (21) |
| Allogeneic | CY | AA | 10 | Mean 23 | Mean 2.5 (1–15) | 90% | 4 live births in 4 patient’s partners | (22) |
| Allogeneic | CY/TBI (10 Gy) | HM | 59 | 23 (12–59) | 5 (1–19) | 20% | 8 live births in 8 pregnancies of 5 patient’s partners | (21) |
| CY/TBI (12 Gy) | HM | 226 | 31 (11–62) | 4 (1–14) | 16% | |||
| CY/TBI (>12 Gy) | HM | 166 | 26 (13–54) | 4 (1–13) | 18% | |||
| Allogeneic | CY/TBI (9.5–14.4 Gy) | HM | 11 | 33 (19–47) | 3 (1–9) | 9% | NA | (23) |
| Allogeneic | CY/TBI or CY/TAI | HM | 48 | mean 27 | mean5.6 (1–18) | 15% | 1 live birth in 1 patient’s partner | (22) |
| Allogeneic | BU/CY | HM | 46 | 34 (13–56) | 2 (1–5) | 17% | 4 live births in 4 pregnancies of 2 patient’s partners | (21) |
| Autologous | BEAM | HL, NHL | 10 | 30.5 (17–53) | 2.5 (0.1–5) | 0 | No recovery | (23) |
CY, cyclophosphamide; AA, aplastic anemia; HM, hematological malignancy; NA, not assessed; TAI, thoracoabdominal irradiation; BU, busulfan; BEAM, carmustine, etoposide, cytarabine and melphalan.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
